Earnings Call · Q3 FY2024·2024-11-12

Q3 24EPS -18.42%·Rev n/aQ2 24EPS -2.78%·Rev n/aQ1 24EPS -6.25%·Rev n/aQ4 23EPS -29.09%·Rev n/a⚠ consensus missing

Neumora Therapeutics, Inc. NMRA

Helen Rubinstein — Head of Investor Relations

Henry Gosebruch — Chief Executive Officer

Josh Pinto — Chief Financial Officer

−17.1%1d on move date−16.8% vs SPY3d−14.3%5d−27.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NMRA calls or request research access.

More NMRA calls Browse calls Request research access